Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvalent, Inc. (NUVL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nuvalent is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, and its filings offer detailed information on clinical progress, financing activities, and key business agreements related to its targeted oncology pipeline.
Recent Form 8-K filings describe pivotal and preliminary data for neladalkib in ALK-positive NSCLC from the ALKOVE-1 Phase 1/2 trial, pivotal data for zidesamtinib in ROS1-positive NSCLC from the ARROS-1 Phase 1/2 trial, and the initiation of the ALKAZAR Phase 3 trial in TKI-naïve ALK-positive NSCLC. Other 8-Ks outline the completion and FDA acceptance of a New Drug Application for zidesamtinib in TKI pre-treated ROS1-positive NSCLC, plans for an NDA submission for neladalkib, and the assignment of a PDUFA target action date for zidesamtinib.
Filings also document Nuvalent’s capital markets activity, including an underwriting agreement for a public offering of Class A common stock under an automatically effective shelf registration statement on Form S-3, and the company’s estimate that proceeds from the offering, together with existing cash, cash equivalents, and marketable securities, would fund operations into 2029. Additional disclosures cover a preexisting royalty interest on future net sales of neladalkib and zidesamtinib, as well as periodic 8-Ks furnishing quarterly financial results press releases.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight the main points of each document, helping readers quickly understand clinical data updates, NDA milestones, financing terms, and other material events. Users can review 10-K and 10-Q reports, 8-K current reports, registration statements, and exhibits, and use the AI-generated insights to navigate lengthy technical and legal language more efficiently while researching NUVL.
Nuvalent, Inc. furnished an update indicating that it preliminarily estimates having approximately $1.4 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is described as a preliminary, unaudited estimate as of January 12, 2026 and may change once year-end financial closing procedures are completed, so it does not provide a full picture of the company’s financial condition at that date. The estimate was disclosed via a press release attached as Exhibit 99.1, which is being furnished rather than filed, and the company notes that related statements are forward-looking and subject to risks outlined in its prior SEC reports.
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish reported a mix of stock sales and new equity awards. On January 5–6, 2026, he sold multiple blocks of Nuvalent Class A Common Stock in open-market transactions, including 513 shares at a weighted average price of $96.06, 660 shares at $96.85, 1,137 shares at $97.96, 186 shares at $98.52, 1,106 shares at $96.75, 1,369 shares at $97.33 and 189 shares at $98.40.
According to the footnotes, these sales were made under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations on vesting equity awards. On January 7, 2026, Pelish acquired 17,500 shares of Class A Common Stock for $0.00 pursuant to restricted stock units that vest in three equal annual installments after January 7, 2026, and received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years.
Nuvalent, Inc. Chief Development Officer Darlene Noci reported several sales and equity awards involving the company’s Class A Common Stock. On January 5 and 6, 2026, she sold multiple small blocks of shares under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to satisfy tax withholding obligations upon vesting of earlier equity awards. Reported weighted average sale prices include
On January 7, 2026, Noci reported an acquisition of 17,500 Class A shares for
Nuvalent, Inc. Chief Legal Officer Deborah Ann Miller reported multiple transactions in the company’s Class A Common Stock. On January 5–6, 2026, she sold several small blocks of shares at weighted average prices generally ranging from about $95.34 to $99.10 per share, with the filing noting these sales were made under a durable Rule 10b5-1 sell-to-cover instruction to satisfy tax withholding obligations on previously granted equity awards.
On January 7, 2026, she received 17,500 restricted stock units (RSUs), each representing one share of Class A Common Stock, which vest in three equal annual installments following that date, and a stock option for 17,500 shares at an exercise price of $106.82 that vests in equal monthly installments over four years. After these transactions, she directly beneficially owned 59,634 shares of Class A Common Stock and 17,500 stock options.
Nuvalent, Inc. Chief Medical Officer Christopher Durant Turner reported multiple sales of Class A common stock on January 5–6, 2026, at weighted average prices generally in the $96–$99 range. The filing notes these sales were executed under a durable Rule 10b5-1 sell-to-cover instruction entered into on December 6, 2023 to cover tax withholding on previously vested equity awards.
On January 7, 2026, he reported the acquisition of 17,500 restricted stock units (RSUs), each representing one share of Class A common stock, which vest in three equal annual installments following January 7, 2026, subject to continued service. He also received a stock option for 17,500 shares with an exercise price of $106.82, vesting in equal monthly installments over four years following January 7, 2026.
Nuvalent, Inc. Chief Financial Officer Alexandra Balcom reported several transactions in the company’s Class A common stock. On January 5 and 6, 2026, she sold small blocks of shares at weighted average prices ranging from about $95 to $99 per share under a durable Rule 10b5-1 sell-to-cover instruction, used to satisfy tax withholding on previously granted equity awards. After these sales, she continued to hold tens of thousands of shares directly.
On January 7, 2026, Balcom received 17,500 restricted stock units, each representing one share of Nuvalent Class A common stock. These RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. She was also granted a stock option for 17,500 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years following January 7, 2026, also conditioned on continued service.
Nuvalent, Inc. President and CEO James Richard Porter reported multiple stock transactions in early January 2026. On January 5–6, 2026, he sold several blocks of Nuvalent Class A Common Stock under a pre-arranged Rule 10b5-1 sell-to-cover instruction, with weighted average prices ranging from about $96 to $99 per share to cover tax withholding on previously vested equity awards. After these sales, his directly held shares were reduced to 278,629.
On January 7, 2026, Porter received 46,250 restricted stock units (RSUs) for Class A Common Stock at a stated price of $0.00, increasing his directly held shares to 324,879. The RSUs vest in three equal annual installments following January 7, 2026, subject to continued service. He was also granted a stock option for 46,250 shares at an exercise price of $106.82 per share, vesting in equal monthly installments over four years after January 7, 2026.
Nuvalent, Inc. reports that Royalty Pharma plc has acquired a preexisting royalty interest related to Nuvalent’s neladalkib and zidesamtinib investigational product candidates from an undisclosed third party for up to $315 million. These product candidates are already subject to a revenue share agreement with Nuvalent’s scientific founder, which is described in the company’s Annual Report on Form 10-K for the year ended December 31, 2024.
Nuvalent explains that the “low single digit preexisting royalty” referenced in Royalty Pharma’s announcement is a 1.5% royalty on net sales of both neladalkib and zidesamtinib. This update clarifies the precise royalty rate that would apply to potential future sales of these drug candidates.
Nuvalent, Inc. reported that one of its directors acquired equity on December 10, 2025. The director received 2,837 shares of Class A common stock issuable under restricted stock units at a price of $0.00, bringing direct ownership of Class A common stock to 2,837 shares.
The director also acquired a stock option for 4,418 shares of Class A common stock with an exercise price of $105.74 and an expiration date of December 10, 2035. The RSUs vest in three equal annual installments after December 10, 2025, while the stock option vests over the three years following that date in equal monthly installments, in each case subject to continued service.
Nuvalent, Inc. (NUVL) reported insider stock sales by a director on 11/24/2025. The reporting person sold multiple small blocks of Class A common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2024.
The Form 4 shows sales at weighted average prices ranging from about $107.01 to $110.64 per share, including transactions reported at weighted averages of $107.70, $108.73, $109.77 and $110.42. After these transactions, the reporting person beneficially owned 1,378,387 Class A common shares directly and 201,672 shares indirectly through the Matthew D. Shair 2021 Irrevocable Family Trust, over which the reporting person has voting and dispositive power.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
